Filing Flows › ADC Therapeutics SA (ADCT) › Q1 2026
ADC Therapeutics SA (ADCT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 4, 2026
ADC Therapeutics SA (ADCT) reported revenue of $20.9M for the first quarter 2026 (Q1 2026), -9% from a year earlier and -10% from the quarter before. Operating margin was -121.1%, net loss $33.0M (158.1% of revenue).
ADC Therapeutics SA, Q1 2026: revenue $20.9M (-10% year over year), operating margin -121.1%, net loss $33.0M, operating cash flow −$29.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.9M | -10% | -9% |
| Operating profit | −$25.2M | — | — |
| Net earnings | −$33.0M | — | — |
| Operating cash flow | −$29.7M | — | — |
What changed
Revenue was $20.9M in Q1 2026, down 9% year over year and down 10% from the previous quarter. Product revenues, net was the largest line at 96% of revenue.
Operating costs exceeded revenue by $25.2M, an operating margin of -121.1%. Total costs fell 10% while revenue fell 9%. The fastest-growing cost line was Other operating costs (+75%). The quarter ended with a net loss of $33.0M, wider than the previous quarter's $6.4M loss.
Operating cash flow was −$29.7M. Non-cash charges added back $2.4M of share-based compensation. Capital expenditures of $32K exceeded it, leaving free cash flow of −$29.7M.
Questions
What was ADC Therapeutics SA's revenue in the first quarter 2026?
ADC Therapeutics SA (ADCT) reported revenue of $20.9M for the first quarter 2026 (Q1 2026), -9% from a year earlier and -10% from the quarter before.
Was ADC Therapeutics SA profitable in the first quarter 2026?
Operating loss was $25.2M (-121.1% of revenue) and net loss $33.0M.